This site uses cookies to ensure the best viewing experience for our readers.
Liron Wand and Jonathan Glazer join Pitango as Venture Partners

Appointment

Liron Wand and Jonathan Glazer join Pitango as Venture Partners

Wand, formerly at Google and Facebook, joins Pitango Growth’s team, and Glazer, the former Head of the Ambulatory Care Service in Tel Aviv Sourasky Medical Center’s Emergency Department, joins the Healthtech team

CTech | 15:17, 10.04.22

Israeli venture capital firm Pitango announced on Sunday that it has appointed two new Venture Partners, Liron Wand and Dr. Jonathan Glazer.

Wand most recently served as Director Partnerships and Business Development at Facebook. She started her career in venture capital working as an analyst in Star Ventures. She later joined Harel-Hertz, a boutique consulting firm specializing in Japan where she had previously spent her teenage years. Over the past 10 years, she led Go-To-Market teams at Kenshoo, Google and Facebook, based out of Silicon Valley. Liron completed her MBA at MIT Sloan in 2011 and last summer returned to Israel with her family after 12 years in the U.S.

Jonathan Glazer(right) and Liron Wand of Pitango. Jonathan Glazer(right) and Liron Wand of Pitango. Jonathan Glazer(right) and Liron Wand of Pitango.

Dr. Jonathan Glazer (MD, MBA) joined as a Venture Partner in the Healthtech fund. Glazer is an Emergency Physician and the former Head of the Ambulatory Care Service in Tel Aviv Sourasky Medical Center’s Emergency Department. Glazer has also held advisory and leadership positions in various startups and companies across the industry, including as Chief Medical Officer & Head of Business Development at Nanose Medical.

Related articles:


Pitango has raised more than $2.8 billion to date and invests via three dedicated funds: Pitango First, Pitango Growth and Pitango HealthTech. Since inception in 1993, Pitango has invested in over 250 companies and saw more than 85 become publicly traded companies, or acquired by strategic players.

share on facebook share on twitter share on linkedin share on whatsapp share on mail

TAGS